Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-label Study of 9-valent HPV Vaccine in Japanese Boys and Girls 9–15 Years
2020-001170-29Phase 3
- Sponsor
- Merck & Co.
- Start
- Feb 2024
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, Cervical Cancer (CC), anal cancer and 2 more, sponsored by Merck & Co. Primary endpoint: Seroconversion Percentages for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 7.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)anal canceroropharyngeal canceranogenital warts
Beyond the preview
Go deeper on 2020-001170-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001170-29.